Freeman Chris, Chief Commercial Officer, has demonstrated a consistent pattern of selling activity in Guardant Health (GH) shares, with no recorded purchases across 37 transactions totaling $5.52 million in proceeds. The bulk of this activity occurred in a concentrated sell-off on December 5, 2025, when Chris disposed of shares in 11 separate transactions worth between $24,312 and $1.22 million, the latter being the single largest sale. This was followed by additional dispositions in early 2026, including a $1.04 million sale on January 1 and a $609,287 transaction on March 15. The filings indicate these were primarily open-market sales (coded "S") with some shares also disposed of through tax withholding obligations (coded "F"). Notably, all transactions since late 2025 have been exits, with no compensatory awards or acquisitions offsetting the sales. The absence of any buy transactions over this 18-month period suggests a directional reduction in Chris's GH holdings, though the retained position size remains undisclosed in these filings. The activity spans multiple price points, with individual sale values ranging from five to seven figures, indicating either a structured liquidation approach or periodic rebalancing tied to vesting events.
AI-assisted summary